The Zhitong Finance App learned that Novartis Pharmaceuticals (NVS.US) ushered in a “double day of ice and fire” in the field of neurology and autoimmunity: the company urgently suspended eight clinical trials of CAR-T therapy due to the deaths of three patients; however, its multiple sclerosis (MS) oral drug remibrutinib achieved positive results in later clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.